The Correlation Between Circulatory Tumor Cells and Venous Thrombosis

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorChang Gung Memorial Hospital

About this trial

Research indicates a strong correlation between cancer and thrombosis, with approximately 20% of blood clots in the U.S. being cancer-related, according to CDC data. Cancer patients face a 4-7 times higher risk of thrombosis compared to non-cancer individuals. Certain cancer treatments, such as chemotherapy and targeted therapy, elevate the likelihood of venous thromboembolism (VTE). Cancer patients with VTE exhibit a significantly higher hazard ratio (H.R.) of 3.4 compared to those without VTE.

This study aims to explore three main topics: (1) Comparing the differences and similarities of leukocyte populations between cancer-associated thrombosis (CAT) and venous thromboembolism (VTE). (2) Characterizing the factors contributing to increased incidence of cancer-associated thrombosis (CAT), with the hypothesis that circulating tumor microemboli (CTM) may express more thrombosis-related proteins than CTCs. (3) Understanding the effects of aspirin or NOACs on cancer-associated thrombosis and CTM formation.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

age≧18

participants (1)participants without cancer: without cancer in five years (2)participants with cancer:pathology reveal have malignant tumor

patients who underwent catheter-based thrombectomy

agree do the thrombectomy

Disqualifiers

participants without cancer (1).shock (2).severe sepsis (3).with cancer in five years

participants with cancer (1).shock (2).severe sepsis

Trial population

patients who underwent catheter-based thrombectomy

Trial design

Design model

Case-only

Time perspective

Cross-sectional

Treatments tested in this trial

  • CTCs/CTMs culture

    Procedure/Surgery

    Collect the thrombosis from participants underwent catheter-based thrombectomy.To characterized by cancer-specific surface markers successfully and identify within the culture

Treatment groups

120 Participants
are divided into 2 treatment groups
Group A: cancer for CTC culture1 intervention
Group B: health for CTC culture1 intervention

Trial outcomes

Primary outcomes

1

cell culture

cancer-specific surface markers

Time frame
baseline
2

RNA-seq

DNA/RNA extraction of sorted cells as instruments' maneuvers and do the RNA-seq

Time frame
baseline

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.